PIK3CD and B-cell chronic lymphocytic leukemia: Therefore, thorough investigations of the TME in these trials are essential to elucidate the role of PI3K class I isoforms on the function of distinct cell types and to reassure that PI3K inhibitors can serve as a highly active, safe, and tolerable treatment option in CLL.